RxDoctor Payments Data

Navpreet Singh

Family · Smithtown, NYNPI 1548967656

Payments from drug & device makers

$2,851in general payments, 2019–2025

Across 147 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scilex Pharmaceuticals Inc.$1K
  • Nalu Medical, Inc.$372
  • Valinor Pharma, LLC$205
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$199
  • Collegium Pharmaceutical, Inc.$193
  • AbbVie$191
  • plus $563 from 9 others

What the payments were for

  • Travel & lodging$1716%
  • Food & beverage$2,68094%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,851 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$115,361
Medicare patients
117
Services billed
1,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide26$63,755
BelbucaBuprenorphine Hcl76$63,144
Xtampza ErOxycodone Myristate88$56,281
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen527$49,004
Nurtec OdtRimegepant Sulfate11$33,700
OxycontinOxycodone Hcl42$22,505
ProlateOxycodone Hcl/Acetaminophen12$20,953
UbrelvyUbrogepant11$16,404
MovantikNaloxegol Oxalate42$16,238
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen325$12,008
Nucynta ErTapentadol Hcl11$11,624
Buprenorphine37$9,273
Oxycodone Hcl360$7,842
Diclofenac Sodium115$6,414
Lidocaine67$6,012

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er$193$131,049175 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$199$63,75526 claims
PfizerNurtec Odt$22$33,70011 claims
Forte Bio-pharma LLCProlate$97$20,95312 claims
AbbVieUbrelvy$191$16,40411 claims
Scilex Pharmaceuticals Inc.Ztlido$1,127$5,53212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in Smithtown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →